Search Results
Oct 21, 2025, 08:36 ET 4 in 5 Home Sellers Who Choose to Forgo a Real Estate Agent Don't Know What Realtor Commission Costs
agent-represented sellers say their agent priced their home correctly. On average, they earned $6,225 more in profit than unrepresented sellers — $138,477 vs. $132,252. Additionally, 85% of represented sellers were satisfied with their profit, compared to 75% of unrepresented sellers.
More news about: Clever Offers
Oct 21, 2025, 06:00 ET TNL Mediagene (NASDAQ TNMG) Publicly Files H1 2025 Earnings Release Supplement Presentation
result in more revenue being generated in H2 2025 vs. H1 2025 Margin Comparability: 4 main factors impacted the comparability of H1 2025 margins vs. H1 2024 margins:
More news about: TNL Mediagene
Oct 21, 2025, 06:00 ET Learning Heroes Releases New Report: Centering Families in the Future of Education
surfaces, at a glance: Mind the gap: Perception vs. reality. Nearly 88% of parents believe their child is at/above grade level in reading and math, yet national benchmark data indicate closer
More news about: Learning Heroes
Oct 21, 2025, 06:00 ET Danaher Reports Third Quarter 2025 Results
% Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period
More news about: Danaher Corporation
Oct 21, 2025, 02:00 ET Haut.AI Launches Ground Breaking GenAI Powered Skin Aging Simulation
outcomes. Reinvent Product Storytelling: By illustrating side-by-side scenarios – such as "with vs. without" the use of key actives – SkinGPT makes complex dermatological science both visual and persuasive. This storytelling power creates new opportunities
More news about: Haut.AI
Oct 20, 2025, 17:46 ET ManaMed® Secures FDA 510(k) Clearance for PlasmaFlow® X -- a Breakthrough, Compact Sequential Compression System with All-Day Battery
shelf space in surgery centers and warehouses nationwide—while reducing packaging waste. With an all–day battery that offers double the battery life vs. the previous PlasmaFlow model, the latest controller architecture, and USB–C charging, it's built for seamless, everyday use at home and across care
More news about: ManaMed LLC
Oct 20, 2025, 12:00 ET Confidence Without Clarity: New Study Reveals America's Financial Literacy Gap
Key Findings: Confidence vs. Literacy: Over half of respondents expressed high confidence in their financial acumen, yet only 51% answered four or five basic financial literacy
More news about: Transamerica
Oct 20, 2025, 11:25 ET VITAL WorkLife Launches Reimagined Digital Platform and Mobile App to Revolutionize Access to Mental Health and Well-Being Support
Enhanced Personalization: Content and resources are customized based on the member's role (e.g., specific clinical resources for providers vs. general resources for employees). Confidential and Secure: The platform is designed for immediate,
More news about: VITAL WorkLife
Oct 20, 2025, 11:21 ET Cleaning Beats Karak: Clorox Brain Study Reveals Unexpected Mood Booster
A new neuroscience-led experiment by Clorox in the UAE and KSA used EEG headsets to measure real-time brain responses during cleaning vs. feel good rituals. Participants experienced a 20% higher "Feel Good Index"
More news about: Clorox Arabia
Oct 20, 2025, 10:23 ET Cleaning Beats Karak: Clorox Brain Study Reveals Unexpected Mood Booster
A new neuroscience-led experiment by Clorox in the UAE and KSA used EEG headsets to measure real-time brain responses during cleaning vs. feel good rituals. Participants experienced a 20% higher "Feel Good Index"
More news about: Clorox Arabia
Oct 20, 2025, 08:03 ET No Compromises. Just Quality. Dymatize Launches New Creatine Monohydrate with Creapure®
training†‡. Available on Amazon and priced at just $19.99 for 300 grams, 33 cents per serving, Dymatize Creatine Monohydrate delivers up to 30% value vs. the leading creatine SKU. Dymatize Creatine Monohydrate is science-backed to support muscle & strength building†‡, high-intensity
More news about: Dymatize
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
months in the Control Arm, HR 0.84, p-value = 0.1712.Event-free rate favors Sirexatamab Arm beginning at month 9 (53 vs 47%) with further separation at month 12 (34 vs 23%). Sirexatamab, in combination with chemotherapy and bevacizumab, was safe and well tolerated
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Status: STEP and OASIS 4 Post Hoc Analysis. Poster presentation – Wednesday 5 November; 2:30-3:30 PM ET Oral vs. Injectable Semaglutide: An Indirect Treatment Comparison of Weight Loss Outcomes. Poster presentation – Wednesday 5 November; 2:30-3:30 PM
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Status: STEP and OASIS 4 Post Hoc Analysis. Poster presentation – Wednesday 5 November; 2:30-3:30 PM ET Oral vs. Injectable Semaglutide: An Indirect Treatment Comparison of Weight Loss Outcomes. Poster presentation – Wednesday 5 November; 2:30-3:30 PM
More news about: NOVO NORDISK INC.
Oct 20, 2025, 06:16 ET ACG METALS LIMITED: Q3 2025 YTD Operations and Capital Structure Update
vs Q3 YTD 2024
More news about: ACG METALS LIMITED
Oct 20, 2025, 06:00 ET Realtor.com®: Down Payments Steady as Average FICO Scores Remain At 10-Year High
vs 2019
More news about: Realtor.com
Oct 20, 2025, 02:50 ET 2025 ESMO主席論壇口頭報告|維迪西妥單抗一線治療尿路上皮癌RC48-C016研究實現重大突破
1+/2+/3+）。在接受HER2檢測的765例患者中，632例患者具有HER2表達的特徵（IHC 1+/2+/3+），約占接受HER2檢測患者人群的82.6%。該研究共納入484例患者，以1:1方式隨機分組。本研究設計中預設了分層因素，主要包括順鉑是否耐受、HER2表達狀態（HER2 IHC 1+ vs IHC 2+/3+）及是否有內臟轉移情況等。 結果顯示，維迪西妥單抗聯合特瑞普利單抗方案的療效獲益在所有預設亞組中均表現一致。無論患者HER2表達狀態及順鉑耐受性如何，無論腫瘤發生於上尿路還是下尿路，維迪西妥單抗聯合特瑞普利單抗相比化療均顯著改善PFS和OS，有力證明了其在尿路上皮癌全人群的獲益。
More news about: 榮昌生物製藥（煙台）股份有限公司
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
to groups. Stratification factors were pre-specified in the study design, primarily including cisplatin eligibility, HER2 expression status (IHC 1+ vs. IHC 2+/3+), and presence of visceral metastasis. The results showed that the efficacy observed in the disitamab vedotin plus toripalimab
More news about: RemeGen Co., Ltd
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
Median PFS was significantly longer in trastuzumab botidotin than in T-DM1 (11.1 months vs 4.4 months; HR: 0.39, 95% CI, 0.30-0.51, p<0.0001). PFS benefit with trastuzumab botidotin was consistently observed regardless of prior lines of
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
Sac-TMT significantly improved ORR as compared to chemotherapy (60.6% vs 43.1%)
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 19:30 ET IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
mean change in GA lesion growth area was reduced by 40.5% from month 24 (mm2/year) vs. projected sham in participants who switched from IZERVAY EM or EOM to IZERVAY EM at 3.5 years, and by 37% vs. projected sham in the IZERVAY EM group who previously received sham (p<0.001 for each). Earlier
More news about: Astellas Pharma Inc.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
clinical presentations, with central-type squamous carcinoma accounting for approximately 63% of the total patients (66.9% in the ivonescimab group vs. 59.4% in the tislelizumab group), consistent with real-world patient distribution. PD-L1 expression levels also reflected those seen in real-world clinical
More news about: Akeso, Inc.
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
collaboration and exclusive license agreement in territories outside of China. Iza-bren has shown a BICR-assessed ORR of 54.6% vs. 27.0% (Odds Ratio 3.3; 95% confidence interval 1.9-5.8; p<0.0001). Median duration of response (DoR) was 8.5 months for iza-bren versus 4.8 months
More news about: SystImmune, Inc.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
As at the data cut-off date January 22, 2025, the median PFS was significantly longer in sac-TMT than in ICC (8.3 vs. 4.1 months; HR, 0.35; 95% CI, 0.26-0.48; P<0.0001). Clinical benefit was seen in sac-TMT independent of HER2 expression (HR for PFS in HER2-zero:
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
including age, gender, smoking status and PD-L1 status as well as protocol-defined stratification groups based on cisplatin ineligibility (ineligible vs eligible but declined), clinical stage and geographic region. The safety results in EV-303 were consistent with those previously
More news about: Astellas Pharma Inc.